This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2022 Apr 1;140(4):335-336.

doi: 10.1001/jamaophthalmol.2021.6376.

Teprotumumab vs Intravenous Methylprednisolone for Thyroid Eye Disease: Is There Still a Role for Steroids?

Ashley A Campbell¹

Affiliations

PMID: 35175298
DOI: 10.1001/jamaophthalmol.2021.6376

Comment

Teprotumumab vs Intravenous Methylprednisolone for Thyroid Eye Disease: Is There Still a Role for Steroids?

Ashley A Campbell. JAMA Ophthalmol. 2022.

. 2022 Apr 1;140(4):335-336.

doi: 10.1001/jamaophthalmol.2021.6376.

Author

Ashley A Campbell¹

Affiliation

¹ Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland.

PMID: 35175298
DOI: 10.1001/jamaophthalmol.2021.6376

No abstract available

PubMed Disclaimer

Comment on

Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease: A Meta-analysis and Matching-Adjusted Indirect Comparison.
Douglas RS, Dailey R, Subramanian PS, Barbesino G, Ugradar S, Batten R, Qadeer RA, Cameron C. Douglas RS, et al. JAMA Ophthalmol. 2022 Apr 1;140(4):328-335. doi: 10.1001/jamaophthalmol.2021.6284. JAMA Ophthalmol. 2022. PMID: 35175308 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems